Second messenger systems and psychoactive drug action: focus on the phosphoinositide system and lithium
- PMID: 2571304
- DOI: 10.1176/ajp.146.10.1251
Second messenger systems and psychoactive drug action: focus on the phosphoinositide system and lithium
Abstract
Most models of psychotropic drug action have emphasized effects on the release or uptake of neurotransmitters as well as interactions with receptors. Stimulation of neurotransmitter receptors triggers a complex array of electrical and biochemical actions. Recent experimental advances have greatly clarified the second messenger systems underlying neurotransmitter actions, suggesting novel sites of action for psychotropic agents. The authors emphasize the phosphoinositide system and the implications of its involvement for the therapeutic actions of lithium.
Comment in
-
The inositol second messenger system.Am J Psychiatry. 1990 Jul;147(7):955. doi: 10.1176/ajp.147.7.955a. Am J Psychiatry. 1990. PMID: 2356890 No abstract available.
Similar articles
-
The inositol second messenger system.Am J Psychiatry. 1990 Jul;147(7):955. doi: 10.1176/ajp.147.7.955a. Am J Psychiatry. 1990. PMID: 2356890 No abstract available.
-
Is the Na(+)-K(+)-ATPase the link between phosphoinositide metabolism and bipolar disorder?J Neuropsychiatry Clin Neurosci. 1993 Fall;5(4):361-8. doi: 10.1176/jnp.5.4.361. J Neuropsychiatry Clin Neurosci. 1993. PMID: 8286932 Review.
-
Initiation and adaptation: a paradigm for understanding psychotropic drug action.Am J Psychiatry. 1996 Feb;153(2):151-62. doi: 10.1176/ajp.153.2.151. Am J Psychiatry. 1996. PMID: 8561194 Review.
-
Molecular neurobiology for practicing psychiatrists, part 2: how neurotransmitters activate second messenger systems.J Clin Psychiatry. 1999 Oct;60(10):647-8. doi: 10.4088/jcp.v60n1001. J Clin Psychiatry. 1999. PMID: 10549679
-
Brief chronic effects of lithium administration on rat brain phosphoinositides and phospholipids.J Neurosci Res. 1991 Mar;28(3):428-33. doi: 10.1002/jnr.490280316. J Neurosci Res. 1991. PMID: 1649922
Cited by
-
Multiple Drug Treatments That Increase cAMP Signaling Restore Long-Term Memory and Aberrant Signaling in Fragile X Syndrome Models.Front Behav Neurosci. 2016 Jun 30;10:136. doi: 10.3389/fnbeh.2016.00136. eCollection 2016. Front Behav Neurosci. 2016. PMID: 27445731 Free PMC article.
-
Effect of lithium maintenance therapy on thyroid and parathyroid function.J Psychiatry Neurosci. 1999 May;24(3):227-33. J Psychiatry Neurosci. 1999. PMID: 10354657 Free PMC article.
-
A Randomized, Double-Blind, Controlled Clinical Trial of Omega-3 Fatty Acids and Inositol as Monotherapies and in Combination for the Treatment of Pediatric Bipolar Spectrum Disorder in Children Age 5-12.Psychopharmacol Bull. 2022 Oct 27;52(4):31-51. Psychopharmacol Bull. 2022. PMID: 36339275 Free PMC article. Clinical Trial.
-
Chronic lithium attenuates dopamine D1-receptor mediated increases in acetylcholine release in rat frontal cortex.Psychopharmacology (Berl). 1996 May;125(2):162-7. doi: 10.1007/BF02249415. Psychopharmacology (Berl). 1996. PMID: 8783390
-
Pharmacological reversal of synaptic plasticity deficits in the mouse model of fragile X syndrome by group II mGluR antagonist or lithium treatment.Brain Res. 2011 Mar 22;1380:106-19. doi: 10.1016/j.brainres.2010.11.032. Epub 2010 Nov 12. Brain Res. 2011. PMID: 21078304 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources